Maplight Therapeutics (NASDAQ:MPLT) Director George Pavlov Purchases 10,658 Shares

Maplight Therapeutics, Inc. (NASDAQ:MPLT) Director George Pavlov bought 10,658 shares of the company’s stock in a transaction on Wednesday, February 18th. The stock was bought at an average price of $17.48 per share, for a total transaction of $186,301.84. Following the completion of the purchase, the director directly owned 10,658 shares in the company, valued at approximately $186,301.84. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website.

George Pavlov also recently made the following trade(s):

• On Friday, February 20th, George Pavlov purchased 9,920 shares of Maplight Therapeutics stock. The shares were purchased at an average cost of $17.86 per share, for a total transaction of $177,171.20.
• On Thursday, February 19th, George Pavlov acquired 4,422 shares of Maplight Therapeutics stock. The shares were acquired at an average price of $17.57 per share, for a total transaction of $77,694.54.

Maplight Therapeutics Trading Down 0.2%

Shares of MPLT stock opened at $17.88 on Friday. The stock has a market cap of $811.22 million and a P/E ratio of -0.48. Maplight Therapeutics, Inc. has a 1-year low of $12.24 and a 1-year high of $21.55. The stock’s fifty day simple moving average is $17.93.

Maplight Therapeutics (NASDAQ:MPLT) last posted its earnings results on Thursday, December 4th. The company reported ($37.18) EPS for the quarter, missing analysts’ consensus estimates of ($1.86) by ($35.32).

Analyst Upgrades and Downgrades

Several research firms have issued reports on MPLT. Zacks Research upgraded shares of Maplight Therapeutics to a “hold” rating in a research note on Monday, November 24th. Stifel Nicolaus initiated coverage on shares of Maplight Therapeutics in a research note on Friday, November 21st. They set a “buy” rating and a $28.00 target price for the company. Jefferies Financial Group initiated coverage on Maplight Therapeutics in a report on Friday, November 21st. They issued a “buy” rating and a $32.00 price target on the stock. Weiss Ratings assumed coverage on shares of Maplight Therapeutics in a report on Thursday, January 22nd. They issued a “sell (e)” rating on the stock. Finally, Wall Street Zen raised Maplight Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, December 20th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $31.00.

Hedge Funds Weigh In On Maplight Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Fcpm Iii Services B.V. bought a new stake in Maplight Therapeutics during the fourth quarter worth about $56,672,000. T. Rowe Price Investment Management Inc. bought a new stake in Maplight Therapeutics during the 4th quarter worth approximately $49,154,000. Goldman Sachs Group Inc. purchased a new stake in shares of Maplight Therapeutics in the fourth quarter valued at about $34,026,000. Nan Fung Group Holdings Ltd purchased a new position in Maplight Therapeutics in the fourth quarter valued at about $17,060,000. Finally, 5AM Venture Management LLC purchased a new position in shares of Maplight Therapeutics in the fourth quarter valued at $16,687,000.

About Maplight Therapeutics

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.